Alderys

Alderys operates at the intersection of biotechnology and industrial chemistry, specializing in the biological engineering of chemical compounds from renewable plant-based resources. Founded in 2009 by Dominique Thomas, a recognized specialist in yeast genetics and metabolism, the company was established to provide a competitive alternative to petrochemical processes. Thomas's background includes roles as Research Director at CNRS, founder and CEO of Cytomics Systems, and experience leading a technology incubator, which provided a strong foundation for Alderys's focus on industrial applications of microbial science.

The core of Alderys's business involves modifying and improving yeast cells, specifically Saccharomyces cerevisiae (baker's yeast), to function as microscopic production units. This proprietary fermentation process transforms non-food sugars and plant waste into valuable chemical compounds. The company's business model is centered on developing these bio-production processes and partnering with major industrial clients. Alderys primarily serves three key markets: commodity chemicals, by creating bio-based 'building block' compounds for products like plastics and solvents; the animal nutrition sector; and the cosmetics industry, for which it develops active ingredients. Before its acquisition, the company had established partnerships with leaders in all three sectors.

Alderys's technological advantage stems from a suite of proprietary platforms, including G-DESIGNER™ for yeast genome engineering, SPRINT-CATALYST™ for improving enzymes, and EVOLEV™ for the controlled evolution of microbe populations. These technologies enable the company to design and accelerate the creation of new biosynthesis pathways, making the production of both existing and novel compounds economically viable. A significant milestone in the company's history was its acquisition by Givaudan, a global leader in flavors and fragrances, which was completed in August 2020. The acquisition was a strategic move for Givaudan to expand its portfolio of natural and bio-sourced products, particularly for its Fragrance and Active Beauty businesses. Alderys's business represented approximately €3 million in incremental revenues for Givaudan in 2019.

Keywords: biological engineering, yeast genetics, fermentation, renewable chemicals, metabolic engineering, biosynthesis, active cosmetic ingredients, animal nutrition, bio-production, Givaudan acquisition, Dominique Thomas, sustainable chemistry, microbial engineering, Saccharomyces cerevisiae, industrial biotechnology, specialty chemicals, bio-based compounds, green chemistry, white biotechnology, synthetic biology